Extended Data Fig. 2: Breadth of FNI mAbs across the Influenza A and B viruses.
From: A pan-influenza antibody inhibiting neuraminidase via receptor mimicry
a, FACS gating strategy used to assess binding of FNI and 1G01 mAbs to NA transiently expressed in mammalian cells. b, Inhibition of NA enzymatic activity by the anti-NA mAbs against group 1 (N1), group 2 (N2) IAV and B/Victoria/2/87-like (Vic) and B/Yamagata/16/88-like (Yam) IBV NA antigens as measured by MUNANA assay. Data represent n = 1 biologically independent experiment out of two. c, Introduction and spreading of the 245 glycosylation motif in H3N2 seasonal viruses. GISAID analysis (2011–2022) of the N2 NAs from seasonal H3N2 strains bearing S245N and S247T mutations, which results in the introduction of the N245 glycosylation site. X represents strains selected for inclusion in the vaccine formulations. Source: Nextstrain (https://nextstrain.org/flu/seasonal/h3n2/na/12y?c=gt-NA_245,247&dmin=2004-10-11).
